McMurray, Pa. (November 13, 2017) – Pennsylvania American Water today announced the start of a water main relocation project in the City of Pittsburgh as part of the City’s planned replacement of the bridge at the intersection of Carnahan and Banksville Roads. The approximately $500,000 project is necessary to relocate nearly 700 feet of existing water main along Camden Avenue.
During construction, crews will close portions of Banksville and Carnahan Roads between November 13 and December 15. The posted detour is Potomac Avenue between Greentree and Banksville Roads.
Subsequently, portions of Wenzell Avenue between Tole Street and Banksville Road will be closed between December 15 and January 15. The posted detour will be Broadway Avenue to Banksville Road. The company expects to complete the main relocation by the end of January 2018,weather permitting, and final paving restoration is scheduled for spring of 2018, also weather permitting.
Pennsylvania American Water, a subsidiary of American Water (NYSE: AWK), is the largest investor-owned water utility in the state, providing high-quality and reliable water and/or wastewater services to approximately 2.3 million people. With a history dating back to 1886, American Water is the largest and most geographically diverse U.S. publicly traded water and wastewater utility company. The company employs more than 6,800 dedicated professionals who provide regulated and market-based drinking water, wastewater and other related services to an estimated 15 million people in 47 states and Ontario, Canada. More information can be found by visiting www.amwater.com.
This release contains forward looking statements, including, among others, our plan to continue our long-term strategy of capital investment in our systems. There are important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements including: general economic business conditions, unfavorable weather conditions, changes in regulations or regulatory treatment and availability and the cost of capital. We undertake no obligation to publicly update or revise any forward-looking statement.
# # #